Home › Funds › Casdin Capital › RXRX

Casdin Capital position in RXRX

RECURSION PHARMACEUTICALCLASS A · Health Care

Casdin Capital reported holding 165,323 shares of RXRX (RECURSION PHARMACEUTICALCLASS A) in its Q2 2026 13F filing — a position valued at US$607K, representing 0.03% of its reported portfolio and ranking #41 among its reported holdings. Casdin Capital has disclosed RXRX holdings in 11 of the last 21 reported quarters, going back to Q2 2021.

Latest position (Q2 2026)165.32K sh
Reported value held$606.74K
Portfolio Weight0.03%
First reportedQ2 2021
Last changeHold
Updated2026-10-05

Last updated: 2026-10-05 · Source: SEC EDGAR Form 13F-HR

How Casdin Capital's RXRX position evolved

Casdin Capital first disclosed a stake in RXRX in Q2 2021 at 548,156 shares (US$20.0M). Across 11 filings, Casdin Capital held the position steady without any share-count change. The most recent filing (Q2 2026) shows 165,323 shares valued at US$607K.

Quarter by quarter

QuarterSharesValueChange
Q2 2021 548.16K $20.01M New
Q3 2021 548.16K $12.61M Hold
Q4 2021 548.16K $9.39M Hold
Q1 2022 548.16K $3.92M Hold
Q4 2024 165.32K $1.12M New
Q1 2025 165.32K $874.56K Hold
Q2 2025 165.32K $836.53K Hold
Q3 2025 165.32K $806.78K Hold
Q4 2025 165.32K $676.17K Hold
Q1 2026 165.32K $507.54K Hold
Q2 2026 165.32K $606.74K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RXRX and 13F data

RXRX (RECURSION PHARMACEUTICALCLASS A) is a Health Care company. 29 other funds we track also report a position in RXRX — the largest reported positions include ARK Invest (US$151.7M), SOFTBANK GROUP CORP. (US$50.0M), MIC Capital Management UK LLP (US$35.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RXRX

All RXRX fund holders →

FAQ

How long has Casdin Capital held RXRX?

Casdin Capital has disclosed RXRX holdings in 11 of the last 21 reported quarters, going back to Q2 2021.

What is Casdin Capital's current position in RXRX?

As of Q2 2026, Casdin Capital holds 165.32K shares of RXRX (RECURSION PHARMACEUTICALCLASS A), valued at $606.74K, representing 0.03% of its reported portfolio and ranking #41.

Has Casdin Capital been buying or selling RXRX?

In the latest 13F filing (Q2 2026), Casdin Capital held unchanged its position in RXRX.

Which other funds hold RXRX?

Other major institutional holders of RXRX include ARK Invest, SOFTBANK GROUP CORP., MIC Capital Management UK LLP, among 29 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.